2026 Mars Shot Grant - Early Detection of Prostate Cancer supports researchers studying nuclear medicine for Stage I–II prostate cancer to improve patient management, potential survival, and quality of life.
Funder: Society of Nuclear Medicine and Molecular Imaging
Due Dates: November 9, 2026 (Applications open) | January 5, 2027 (Application deadline)
Funding Amounts: $100,000
Summary: Supports nuclear medicine research to improve patient management, potential overall survival, and quality of life in early-stage prostate cancer (Stage I–II).
Key Information: The principal investigator must be an active SNMMI member.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) offers this grant through its Mars Shot Research Fund to support nuclear medicine research addressing early-stage prostate cancer (Stage I–II). Proposed work should focus on improving patient management, potential overall survival, and quality of life.
The Mars Shot Research Fund was created to translate visionary nuclear medicine imaging, radiopharmaceutical therapy, and data science research into tools or treatments that improve patients’ lives. This call addresses a disease that affects more than 300,000 men and accounts for approximately 35,000 deaths annually in the United States. Review emphasizes relevance to the Mars Shot initiative, innovation, scientific reasoning, and appropriate methodology.